Jeremy Skillington on Poolbeg's Rare Disease Strategy \u0026 New Developments

(8:32)

Interview with CEO, Jeremy Skillington from Poolbeg Pharma

(12:57)

Poolbeg Pharma's Allmond hopes to replicate Amryt success

(9:30)

Scientific Advisor at Poolbeg Pharma

(4:1econd)

Poolbeg Pharma \

(8:7)

VP of Regulatory Affairs of Poolbeg Pharma

(3:24)

Non-Executive Director Professor Luke O'Niell on POLB 001 \u0026 AI

(4:)

DESTINY PHARMA PLC - XF product pipeline

(2:6:37)

POOLBEG PHARMA PLC - POLB 001 Update

(45:11)

Poolbeg Pharma makes \

(5:1econd)

The Pharma Licensing Process Overview - a Presentation by David Scott

(4:33)

Accesso Technology Group sees \

(5:9)

Open Orphan's CEO talks through name change and a first half 'full of highlights'

(7:11)

Nano One finishes cathode evaluation project and expands collaboration with automotive company

(3:59)

Poolbeg Pharma Plc beings trading on the OTCQB platform to attract more US investors

(5:41)

Greggs’ sausage roll dilemma, the battle for Christmas shoppers, and UK pawnbroking as gold exposure

(51:9)

CytoReason Presentation at PMWC - Liat Dassa - Immunology Team Leader

(13:42)

Poolbeg Pharma makes virus \

(4:26)

Poolbeg Pharma's new NED looking at \

(4:53)

Professor Luke O'Neill background and reasons for joining Poolbeg Pharma

(1:8)

Poolbeg Pharma #POLB - CEO Jeremy Skillington talks to Alan Green

(16:36)

Immense promise for cashed up Poolbeg Pharma

(11:50)

Poolbeg Pharma FY Results:“ we’ve selected our development processes to be very cost efficient”

(15:19)

Poolbeg Pharma's Jeremy Skillington presents new deal with AI in developing new RSV drugs

(4:28)

Jeremy Skillington Poolbeg Pharma Overview

(1:53)

Poolbeg Pharma and CytoReason talk up unique AI opportunity to advance flu treatments

(8:10)

Elfen Lied - Lilium Full - High Quality

(3:2)

Poolbeg Pharma #POLB August 2023 - CEO Jeremy Skillington talks to Alan Green

(12:45)

Poolbeg Pharma wins first non-dilutive grant funding

(3:28)

Poolbeg Pharma \

(7:1econd)